Scotiabank Issues Positive Forecast for Pfizer (NYSE:PFE) Stock Price

Pfizer (NYSE:PFE) had its target price raised by analysts at Scotiabank from $33.00 to $35.00 in a research note issued on Wednesday, Benzinga reports. The firm currently has a “sector outperform” rating on the biopharmaceutical company’s stock. Scotiabank‘s price target would suggest a potential upside of 13.66% from the stock’s previous close.

A number of other research firms also recently issued reports on PFE. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Saturday, October 10th. Cantor Fitzgerald raised their price target on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research report on Thursday, October 8th. Royal Bank Of Canada lifted their price objective on Pfizer from $25.00 to $28.00 and gave the company a “sector perform” rating in a report on Wednesday. Bank of America cut their price objective on Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, July 10th. Finally, Citigroup increased their target price on Pfizer from $27.00 to $30.00 and gave the stock a “neutral” rating in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $29.12.

Pfizer Price Performance

NYSE PFE traded up $0.79 during trading on Wednesday, reaching $30.79. 50,321,531 shares of the company traded hands, compared to its average volume of 39,819,855. The stock’s 50 day moving average price is $28.64 and its two-hundred day moving average price is $26.84. Pfizer has a 1-year low of $23.62 and a 1-year high of $31.06. The company has a market cap of $175.52 billion, a price-to-earnings ratio of 40.52, a P/E/G ratio of 2.08 and a beta of 0.31. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.96 and a current ratio of 1.27.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.13. The company had revenue of $16.58 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%. The business’s revenue was down .4% on a year-over-year basis. During the same period last year, the business earned $0.87 earnings per share. As a group, analysts anticipate that Pfizer will post 2.94 EPS for the current year.

Institutional Investors Weigh In On Pfizer

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new position in shares of Pfizer in the second quarter valued at $1,049,602,000. BlackRock Inc. boosted its holdings in shares of Pfizer by 6.3% during the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock worth $12,754,464,000 after acquiring an additional 31,412,883 shares during the period. Nykredit A S acquired a new position in Pfizer in the 2nd quarter valued at $205,774,000. Assenagon Asset Management S.A. lifted its holdings in shares of Pfizer by 96.0% during the second quarter. Assenagon Asset Management S.A. now owns 11,902,374 shares of the biopharmaceutical company’s stock worth $286,609,000 after buying an additional 5,829,204 shares in the last quarter. Finally, State Street Corp lifted its holdings in shares of Pfizer by 1.8% during the second quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after buying an additional 5,501,032 shares in the last quarter. 68.36% of the stock is owned by institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer beat third-quarter estimates, reporting adjusted EPS of $0.87 and revenue of $16.58 billion. It raised 2026 guidance to $62–$64 billion in revenue and $2.95–$3.05 in adjusted EPS. Article: Pfizer: 3 Key Takeaways for Long-Term Investors
• Positive Sentiment: Growth is increasingly coming from beyond COVID: non-COVID products grew 7% operationally, while launched and acquired products grew 32%. Eliquis, Padcev and other newer medicines helped support results, strengthening the case that Pfizer’s portfolio can offset pandemic-product weakness. Article: Non-COVID Portfolio Steps Up
• Positive Sentiment: Management is also pursuing growth in obesity medicines, with CEO Albert Bourla saying Pfizer aims to bring its past commercial experience to the weight-loss market. That opportunity could add longer-term upside, though it depends on pipeline and development progress. Article: Pfizer CEO Bourla Bets the Viagra Playbook Can Crack the Obesity Market
• Neutral Sentiment: Pfizer appointed company veteran Cecile Guegan permanent CFO after she served as interim CFO. The appointment provides continuity, but the announcement itself offers limited immediate evidence of a change in financial performance. Article: Pfizer Appoints Cecile Guegan as Chief Financial Officer
• Negative Sentiment: Quarterly revenue was nearly flat year over year as Comirnaty and Paxlovid sales declined sharply. This highlights the continuing challenge of replacing pandemic-era revenue and leaves Pfizer reliant on sustained growth from newer products. Article: Pfizer Q3 Revenue and Product Growth
• Negative Sentiment: Analyst views remain restrained: RBC raised its target to $28 but kept a “sector perform” rating, and J.P. Morgan assigned a “Hold.” RBC’s target is below the cited $30.75 share price, signaling limited upside in its assessment. Article: RBC Raises Pfizer Price Target

About Pfizer

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.